COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,556 Articles (22,881 medRxiv, 8,675 bioRxiv)

Most recent first Previous |  Page 1214: Articles 12131-12140  | Next

Disparities in SARS-CoV-2 exposure: evidence from a citywide seroprevalence study in Holyoke, Massachusetts, USA
Matias, W. R., Fulcher, I. R., Sauer, S. M., Nolan, C. P., Guillaume, Y., Zhu, J., Molano, F. J., Uceta, E., Collins, S., Slater, D. M., Sanchez, V. M., Moheed, S., Harris, J. B., Charles, R. C., Paxton, R. M., Gonsalves, S. F., Franke, M. F., Ivers, L. C.
10.1101/2021.10.13.21264975 — Posted: 2021-10-14
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
Wang, P., Casner, R. G., Nair, M. S., Yu, J., Guo, Y., Wang, M., Chan, J. F. W., Cerutti, G., Iketani, S., Liu, L., Sheng, Z., Chen, Z., Yuen, K.-Y., Kwong, P. D., Huang, Y., Shapiro, L., Ho, D. D.
10.1101/2021.10.13.464307 — Posted: 2021-10-14
Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the United States and the United Kingdom: A Randomized Controlled Trial
Sudharsanan, N., Favaretti, C., Hachaturyan, V., Baernighausen, T., Vandormael, A.
10.1101/2021.10.12.21264877 — Posted: 2021-10-14
COVID-19 testing in schools: Perspectives of school administrators, teachers, parents, and students in Southern California
Unger, J. B., Soto, D. W., Lee, R., Deva, S., Shanker, K., Sood, N., Hu, H.
10.1101/2021.10.14.21265000 — Posted: 2021-10-14
Social and mental health risks faced by undocumented migrants during the COVID-19 pandemic: Evidence from three surveys in France
Gosselin, A., Longchamps, C., Oulahal, R., Derluyn, I., Ducarroz, S., Skovdal, M., Verelst, A., Sturm, G., Desgrees du Lou, A., Melchior, M.
10.1101/2021.10.14.21264999 — Posted: 2021-10-14
Variable inhibition of unwinding rates of DNA catalyzed by the SARS-Cov-2 (COV19) helicase nsp13 by structurally distinct single DNA lesions.
Sales, A. H., Ciervo, S., Lupoli, T., Shafirovich, V., Geacintov, N. E.
10.1101/2021.10.13.464299 — Posted: 2021-10-14
Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., Wallace, A. W.
10.1101/2021.10.13.21264966 — Posted: 2021-10-14 Discussion: Onsite
Modelling airborne transmission of SARS-CoV-2 using CARA: Risk assessment for enclosed spaces
Henriques, A., Mounet, N., Aleixo, L., Elson, P., Devine, J., Azzopardi, G., Andreini, M., Rognlien, M., Tarocco, N., Tang, J.
10.1101/2021.10.14.21264988 — Posted: 2021-10-14
Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution
Nunes, D. R., Braconi, C. T., Ludwig-Begall, L., Arns, C. W., Janini, L. M. R., Duraes-Carvalho, R.
10.1101/2021.10.14.21264474 — Posted: 2021-10-14
Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test?
Hofmann, N. E., Grossegesse, M., Neumann, M., Schaade, L., Nitsche, A.
10.1101/2021.10.12.21264881 — Posted: 2021-10-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).